The newest 13F reporting interval has come and gone, and Insider Monkey is once more on the forefront relating to making use of this gold mine of information. We at Insider Monkey have plowed by 866 13F filings that hedge funds and well-known worth traders are required to file by the SEC. The 13F filings present the funds’ and traders’ portfolio positions as of March thirty first. On this article we take a look at what these traders consider Navidea Biopharmaceuticals Inc (NYSE:NAVB).
Navidea Biopharmaceuticals Inc (NYSE:NAVB) shares have not seen a whole lot of motion in the course of the second quarter. Total, hedge fund sentiment was unchanged. The inventory was in 3 hedge funds’ portfolios on the finish of the primary quarter of 2021. Our calculations additionally confirmed that NAVB is not among the many 30 most popular stocks among hedge funds (click on for Q1 rankings). On the finish of this text we may also evaluate NAVB to different shares together with Puhui Wealth Funding Administration Co., Ltd. (NASDAQ:PHCF), Motus GI Holdings, Inc. (NASDAQ:MOTS), and Cyclacel Prescribed drugs Inc (NASDAQ:CYCC) to get a greater sense of its reputation.
To most inventory holders, hedge funds are seen as nugatory, previous monetary autos of the previous. Whereas there are greater than 8000 funds with their doorways open at current, Our specialists take a look at the aristocrats of this membership, round 850 funds. These hedge fund managers orchestrate bulk of all hedge funds’ complete asset base, and by keeping track of their matchless inventory picks, Insider Monkey has unsheathed quite a few funding methods which have traditionally outpaced the broader indices. Insider Monkey’s flagship brief hedge fund technique outpaced the S&P 500 brief ETFs by round 20 proportion factors a 12 months since its inception in March 2017. Additionally, our month-to-month publication’s portfolio of lengthy inventory picks returned 206.8% since March 2017 (by Could 2021) and beat the S&P 500 Index by greater than 115 proportion factors. You possibly can obtain a pattern situation of this text on our website .
John Overdeck of Two Sigma Advisors
At Insider Monkey, we scour a number of sources to uncover the following nice funding concept. For instance, an activist hedge fund needs to purchase this $28 biotech stock for $50. So, we beneficial an extended place to our month-to-month premium publication subscribers. We undergo lists like the ten best battery stocks to choose the following Tesla that can ship a 10x return. Despite the fact that we suggest positions in solely a tiny fraction of the businesses we analyze, we take a look at as many shares as we are able to. We learn hedge fund investor letters and take heed to inventory pitches at hedge fund conferences. You possibly can subscribe to our free day by day publication on our homepage. Protecting this in thoughts we’ll take a look at the brand new hedge fund motion encompassing Navidea Biopharmaceuticals Inc (NYSE:NAVB).
Do Hedge Funds Assume NAVB Is A Good Inventory To Purchase Now?
At Q1’s finish, a complete of three of the hedge funds tracked by Insider Monkey held lengthy positions on this inventory, a change of 0% from the fourth quarter of 2020. However, there have been a complete of 1 hedge funds with a bullish place in NAVB a 12 months in the past. So, let’s take a look at which hedge funds had been among the many prime holders of the inventory and which hedge funds had been making huge strikes.
The most important stake in Navidea Biopharmaceuticals Inc (NYSE:NAVB) was held by Renaissance Technologies, which reported holding $0.3 million value of inventory on the finish of December. It was adopted by Two Sigma Advisors with a $0.3 million place. The one different hedge fund that’s bullish on the corporate was Citadel Funding Group.
Earlier we informed you that the combination hedge fund curiosity within the inventory was unchanged and we view this as a unfavourable improvement. Despite the fact that there weren’t any hedge funds dumping their holdings in the course of the third quarter, there weren’t any hedge funds initiating model new positions. This means that hedge funds, at the perfect, understand this inventory as lifeless cash and so they have not recognized any viable catalysts that may appeal to investor consideration.
Let’s go over hedge fund exercise in different shares – not essentially in the identical business as Navidea Biopharmaceuticals Inc (NYSE:NAVB) however equally valued. We’ll check out Puhui Wealth Funding Administration Co., Ltd. (NASDAQ:PHCF), Motus GI Holdings, Inc. (NASDAQ:MOTS), Cyclacel Prescribed drugs Inc (NASDAQ:CYCC), Hallador Power Co (NASDAQ:HNRG), Crown ElectroKinetics Corp. (NASDAQ:CRKN), MEDIROM Healthcare Applied sciences Inc. (NASDAQ:MRM), and Asia Pacific Wire & Cable (NASDAQ:APWC). All of those shares’ market caps resemble NAVB’s market cap.
[table] Ticker, No of HFs with positions, Complete Worth of HF Positions (x1000), Change in HF Place PHCF,2,252,2 MOTS,6,3178,0 CYCC,8,16256,4 HNRG,4,4536,-1 CRKN,2,371,2 MRM,1,218,1 APWC,2,1076,1 Common,3.6,3698,1.3 [/table]
View table here when you expertise formatting points.
As you may see these shares had a mean of three.6 hedge funds with bullish positions and the typical quantity invested in these shares was $4 million. That determine was $1 million in NAVB’s case. Cyclacel Prescribed drugs Inc (NASDAQ:CYCC) is the most well-liked inventory on this desk. However MEDIROM Healthcare Applied sciences Inc. (NASDAQ:MRM) is the least widespread one with just one bullish hedge fund positions. Navidea Biopharmaceuticals Inc (NYSE:NAVB) is just not the least widespread inventory on this group however hedge fund curiosity continues to be beneath common. Our general hedge fund sentiment rating for NAVB is 32.1. Shares with increased variety of hedge fund positions relative to different shares in addition to relative to their historic vary obtain the next sentiment rating. It is a barely unfavourable sign and we might quite spend our time researching shares that hedge funds are piling on. Our calculations confirmed that top 5 most popular stocks amongst hedge funds returned 95.8% in 2019 and 2020, and outperformed the S&P 500 ETF (SPY) by 40 proportion factors. These shares gained 17.2% in 2021 by June eleventh and surpassed the market once more by 3.3 proportion factors. Sadly NAVB wasn’t practically as widespread as these 5 shares (hedge fund sentiment was fairly bearish); NAVB traders had been upset because the inventory returned -2.5% because the finish of March (by 6/11) and underperformed the market. In case you are involved in investing in massive cap shares with large upside potential, you need to take a look at the top 5 most popular stocks amongst hedge funds as most of those shares already outperformed the market in 2021.
Get real-time e-mail alerts: Comply with Navidea Biopharmaceuticals Inc. (NYSEMKT:NAVB)
Disclosure: None. This text was initially revealed at Insider Monkey.
Associated Content material